XML 70 R59.htm IDEA: XBRL DOCUMENT v3.25.3
COMMITMENTS AND CONTINGENCIES (Details Narrative)
$ / shares in Units, € in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 02, 2025
USD ($)
shares
Jul. 01, 2025
USD ($)
shares
Jan. 16, 2025
USD ($)
shares
Jan. 01, 2024
USD ($)
Dec. 20, 2023
Integer
Aug. 01, 2023
USD ($)
shares
Aug. 31, 2024
USD ($)
Apr. 30, 2022
USD ($)
$ / shares
shares
May 31, 2020
USD ($)
Oct. 31, 2019
USD ($)
Jul. 31, 2019
USD ($)
Sep. 30, 2025
USD ($)
shares
Sep. 30, 2024
USD ($)
shares
Sep. 30, 2025
USD ($)
shares
Sep. 30, 2024
USD ($)
Dec. 31, 2025
USD ($)
Oct. 02, 2025
EUR (€)
Jul. 01, 2025
EUR (€)
Jan. 16, 2025
EUR (€)
Dec. 31, 2024
USD ($)
Apr. 04, 2022
$ / shares
Loss Contingencies [Line Items]                                          
initial cash investment                       $ 12,588,476   $ 12,588,476           $ 6,212,945  
Issuance of shares | shares                         75,000                
Options to acquire shares | shares                                        
Options remaining to be exercised | shares                       31,013   31,013              
BIAKOS License Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Payment for additional royalties                       $ 55,689 $ 36,602 $ 141,124 $ 113,907            
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member]                                          
Loss Contingencies [Line Items]                                          
Royalty percentage                     2.00%                    
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member]                                          
Loss Contingencies [Line Items]                                          
Royalty percentage                     4.00%                    
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member] | Forecast [Member]                                          
Loss Contingencies [Line Items]                                          
Annual royalty                               $ 150,000          
BIAKOS Agreement [Member] | Maximum [Member]                                          
Loss Contingencies [Line Items]                                          
Payment for additional royalties                     $ 1,000,000                    
ABF License Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Increase in royalty annual percentage                   10.00%                      
ABF License Agreement [Member] | Minimum [Member]                                          
Loss Contingencies [Line Items]                                          
Royalty percentage                   2.00%                      
Payment for additional royalties                   $ 50,000                      
ABF License Agreement [Member] | Maximum [Member]                                          
Loss Contingencies [Line Items]                                          
Royalty percentage                   4.00%                      
Payment for additional royalties                   $ 75,000                      
ABF License Agreement [Member] | Maximum [Member] | Product and Service, Other [Member]                                          
Loss Contingencies [Line Items]                                          
Payment for additional royalties                   $ 500,000                      
Debrider License Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Increase in royalty annual percentage                 10.00%                        
Payment of cash or common stock due upon FDA clearance of certain licensed products                 $ 1,000,000                        
Debrider License Agreement [Member] | Rochal [Member]                                          
Loss Contingencies [Line Items]                                          
Payment of cash due upon FDA clearance of certain licensed products                 $ 500,000                        
Debrider License Agreement [Member] | Minimum [Member]                                          
Loss Contingencies [Line Items]                                          
Royalty percentage                 2.00%                        
Annual royalty                 $ 100,000                        
Debrider License Agreement [Member] | Maximum [Member]                                          
Loss Contingencies [Line Items]                                          
Royalty percentage                 4.00%                        
Annual royalty                 $ 150,000                        
Payment for additional royalties                 $ 1,000,000                        
BMI License Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Royalties percentage                           3.00%              
Royalty payments year one                       100,000   $ 100,000              
Royalty payments year two                       200,000   200,000              
Royalty payments year three                       $ 300,000   $ 300,000              
initial cash investment     $ 3,100,000                               € 3.0    
Convertible loan     $ 1,100,000                               1.0    
Number of ordinary shares issued | shares     8,230                                    
Outstanding equity percentage   9.678% 6.67%                                    
Additional contribution | €                                     € 4.0    
Number of exchange of additional ordinary shares | shares   4,116 8,230                                    
Equity investment $ 2,400,000 $ 2,400,000                             € 2.0 € 2.0      
BMI License Agreement [Member] | Subsequent Event [Member]                                          
Loss Contingencies [Line Items]                                          
Outstanding equity percentage 12.499%                                        
Number of exchange of additional ordinary shares | shares 4,114                                        
Precision Healing Merger Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Cash consideration               $ 125,966                          
Payment in cash               $ 600,000                          
Share price | $ / shares                                         $ 30.75
Options to acquire shares | shares               144,191                          
Weighted exercise price | $ / shares               $ 10.71                          
Precision Healing Merger Agreement [Member] | Warrant [Member]                                          
Loss Contingencies [Line Items]                                          
Warrants to purchase shares | shares               4,424                          
Exercise price | $ / shares               $ 7.32                          
Expiration date               Apr. 22, 2031                          
Precision Healing Merger Agreement [Member] | Warrant One [Member]                                          
Loss Contingencies [Line Items]                                          
Warrants to purchase shares | shares               12,301                          
Exercise price | $ / shares               $ 12.05                          
Expiration date               Aug. 10, 2030                          
Precision Healing Merger Agreement [Member] | Accredited Investors [Member]                                          
Loss Contingencies [Line Items]                                          
Issuance of shares | shares               165,738                          
Applied Asset Purchase Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Assets purchase price           $ 15,250,000                              
Installment payable           2,500,000                              
Payment of installment             $ 625,000                            
Applied Asset Purchase Agreement [Member] | Cash Closing Consideration [Member]                                          
Loss Contingencies [Line Items]                                          
Cash consideration paid           $ 9,750,000                              
Applied Asset Purchase Agreement [Member] | Stock Closing Consideration [Member]                                          
Loss Contingencies [Line Items]                                          
Shares issued as consideration | shares           73,809                              
Value of shares issued as consideration           $ 3,000,000.0                              
Applied Asset Purchase Agreement [Member] | Maximum [Member]                                          
Loss Contingencies [Line Items]                                          
Earnout payable           $ 10,000,000.0                              
Services Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Purchase agreement description           As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to 3% of the actual collections from net sales of certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to 5% for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of 2.5% on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million                              
License Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Number of unique collagen peptides | Integer         18                                
Outstanding units percentage         10.00%                                
License Agreement [Member] | Minimum [Member]                                          
Loss Contingencies [Line Items]                                          
Payment for additional royalties       $ 50,000                                  
Royalty expense percentage         1.50%                                
License Agreement [Member] | Minimum [Member] | Royalty Agreement Terms [Member]                                          
Loss Contingencies [Line Items]                                          
Payment for additional royalties       $ 100,000                                  
License Agreement [Member] | Maximum [Member]                                          
Loss Contingencies [Line Items]                                          
Royalty expense percentage         3.00%